Sirolimus vs everolimus: which one has the human aging data?
Every row cites its source. Where a cell reflects our own reading of the evidence rather than an external source, the row says so.
Everolimus is sirolimus's closest approved relative, and most of the celebrated human 'rapamycin' immune data belong to it. The compound_studied column is this table's whole point.
| aspect | sirolimus | everolimus | Source |
|---|---|---|---|
| What it is | The original molecule (rapamycin), isolated 1975 from Easter Island soil bacteria | A modified derivative (rapalog) of sirolimus, developed later | source |
| US approvals | Rapamune (1999): renal-transplant rejection prophylaxis; LAM (2015). Plus HYFTOR gel, FYARRO IV for other uses | Afinitor: oncology (breast, neuroendocrine, renal). Zortress: kidney and liver transplant | source |
| Half-life | About 62 +/- 16 hours | About 30 hours | source |
| Mouse lifespan data | The ITP's replicated extensions (both sexes, 3 sites, late-life start) are sirolimus results | The ITP lifespan papers cited on this page tested sirolimus, not everolimus; mouse work shows everolimus inhibits mTORC1 with less glucose impact | source |
| Elderly immune RCTs | None of the three landmark trials used sirolimus | Mannick 2014: everolimus improved vaccine response about 20%. Mannick 2018: dactolisib plus everolimus cut reported infections (P=0.001) | source |
| Phase 3 aging outcome | Never attempted | The program's phase 3 (RTB101/dactolisib alone) failed its primary endpoint in 1,024 older adults | source |
| Longevity-population RCT | PEARL: 48 weeks, compounded weekly dosing, primary endpoint missed; secondary signals in women | None completed in a healthy longevity population | source |
| Interchangeable? | No. Different labels, PK, and doses | No. Quoting everolimus trials as sirolimus evidence is a compound substitution, which is why our study table names the molecule on every row | source |